The typical muscular symptoms of myasthenia gravis have been attributed to a reduced effect of the neurotransmitter, acetylcholine, on the motor endplate (Grob et al., 1956) . Theoretical arguments that myasthenia gravis might result from interference with the acetylcholine receptor by antibodies were first presented by Simpson (1960) . During the last years experimental evidence has accumulated, pointing to the possibility that the disturbance of neuromuscular function is caused by an autoantibody directed against structures on the postsynaptic membrane of the neuromuscular junction.
In 1973 it was shown by retransfusion experiments that the myasthenic symptoms could be aggravated by a high molecular weight protein, probably an IgG (Bergstrom et al., 1973) . In 1974 came the first report on the existence of a specific immunoglobulin, the acetylcholine receptor antibody, in the sera from the majority of patients with myasthenia gravis (Almon et al., 1974) . These findings have now been confirmed by many other groups (Aharonov et al., 1975; Appel et al., 1975; Lindstrom et al., 1976; Lefvert and Bergstrom, A sensitive and accurate assay allowing quantitative determinations of acetylcholine receptor antibody has now been in routine use for two years in our laboratory. The aim of this study was to evaluate the clinical usefulness of receptor antibody determinations, and their possible implication on the pathogenetic mechanism of myasthenia gravis.
Material and Methods

PREPARATION OF PARTIALLY PURIFIED CHOLINERGIC RECEPTOR FROM HUMAN SKELETAL MUSCLE
Human skeletal muscle was collected from amputated legs at the time of operation. The muscle was immediately frozen and stored at -800C. When used, the muscle was cut into small pieces and homogenised at -+0°C in four volumes of phosphate buffer, 0.05 mol/l with NaCl, 0.1 mol/l and EDTA 0.001 mol/l, pH 7.5 with the addition of Trasylol (Bayer AG, West Germany) to 106 kallikrein inhibitory units/I. The homogenate was centrifuged at 30000 g for 20 minutes at +40C, the pellet washed once, and resuspended in three volumes of the same buffer containing 1.5% Triton X-100. This mixture was stirred at room temperature for 90 minutes and then centrifuged at 30 000 g for 20 min at +40C. The lipid layer was discarded and the supernatant collected and stored in aliquots at -800C. The ability to bind neurotoxin and acetylcholine-receptor antibody did not change during four months of storage.
The binding capacity for 1251-a-neurotoxin (Naja naja siamensis) was determined by incubation of 1 ml of the supernatant with different amounts of toxin at +370C for one hour, followed by gel filtration on Sephacryl G-200 superfine (Pharmacia Fine Chemicals, Sweden) to remove excess toxin. The recovery of toxin binding sites was 1-5 pmoles /g muscle (wet weight).
IODINATION OF NEUROTOXIN
Alpha-neurotoxin from the venom of Naja naja siamensis was kindly supplied by Professor E. Karlsson, Uppsala University, Sweden. The neurotoxin was labelled with 125J using the chloramin-T method (Hunter and Greenwood, 1962) . About 30 nmoles of neurotoxin (225 ,ug) Appel et al. (1975) , and by Lindstrom (1977 (StAlberg and Ekstedt, 1973) . The clinical evaluations of the patients were done at the time of blood sampling by three of us (GM, PO, and RP) using the same standardised inquiry form and standardised tests for muscle strength and physical performance (available on request from the authors). Functions were tested separately for eye muscles, bulbar muscles and the muscles of neck, legs, and arms, and graded, using a scale from 0-4 (0: no symptoms, 4: complete paralysis). The patients were classified by the modified criteria of Ossermann and Oosterhuis in the following stages (Oosterhuis, 1964) Immunosuppressive treatment, thymectomy, and drainage of thoracic duct lymph were performed according to procedures reported elsewhere (Matell et al., 1976 Drainage of thoracic duct lymph was followed by clinical improvement in four out of five patients (Fig. 3) . In the one patient who did not improve, the decrease of receptor antibody concentration in serum was only 10% after one week. The amount of lymph drained was half to one-third of the total plasma volume per day for all patients. The decrease in receptor antibody concentration in serum ranged from 10 to 60%. The reduction of total IgG, however, was more pronounced in all patients (30-85%).
During treatment with ACTH four out of five patients showed a rise of receptor antibody concentration during the first week (Fig. 4) . This rise coincided with the initial clinical worsening usually seen during ACTH treatment in myasthenia gravis, and was followed by a decrease in concentration. Patients on immunosuppressive treatment had significantly lower values of receptor antibody than patients without treatment (P<0.001). When comparing only patients with a positive analysis, the difference between these groups was not significant (P>0.05).
Thymectomy lowered the concentration of receptor antibody (Table 4) The concentration of receptor antibody and IgG was measured both in serum and in cerebrospinal fluid in 24 patients (Table 6 ). Of these, 17 patients had receptor antibody both in the cerebrospinal fluid and in serum. In one patient, receptor antibody could be found only in the cerebrospinal fluid and in one, only in the serum. The quotient between spinal fluid IgG concentration and serum IgG concentration as well as the IgG index [(CSF/S IgG ratio)/(CSF/S albumin ratio)] were normal in all but two cases. The quotient between the spinal fluid receptor antibody concentration and the serum receptor antibody concentration exceeded the corresponding value for IgG by a factor of 2-10 in 11 out of 17 patients. Immunosuppressive treatment 20 10 Samples were also analysed from two mothers with myasthenia gravis and from their newborn children. Both mothers had had mild generalised myasthenia gravis for four and seven years respectively, and one was in complete remission during pregnancy. No medication other than cholinesterase inhibitors was given to the other woman. Pregnancy and delivery were normal for both. The babies were clinically normal. The concentration of receptor antibody was followed in both babies during three weeks after birth (Table 7) .
Receptor antibodies of the IgG type could be demonstrated in cord blood in both babies. The concentration in cord blood was equal to the concentration in maternal serum for one baby (S), and was about 30% higher for the other (P). Repeated examinations showed a fall in concentration to zero values within four weeks. Determination of acetylcholine receptor antibody in myastlienia gravis
All samples where no receptor antibodies of the IgG type could be found were also tested for the presence of antibodies of IgA and IgM type. In all but the five patients described below these analyses were negative.
On analysis of nine patients with a duration of symptoms less than nine months, three patients had receptor antibodies of the IgM type as well as of the IgG type (Fig. 6) .
Two patients had an IgG receptor antibody concentration below 0.2 arbitrary units/l when analysed three and six weeks, respectively, after the beginning of myasthenic symptoms. The concentration of IgM receptor antibody at this first examination was 0.27 and 0.22 arbitrary units/l respectively. The upper 95% limit for the normal pool was 0.12 arbitrary units/I. The concentration of IgM antibodies decreased and that of IgG increased during the following months in both patients.
The third patient had both IgG and IgM type antibodies (3.00 and 0.35 arbitrary units/l respectively). The concentrations did not change during an observation period of four months. In this patient the symptoms began six months before the first analysis. (Lindstrom et al., 1976) even five to 10 years after thymectomy. The occurrence of thymoma in myasthenia gravis is generally coupled with a more severe disease and a less favourable prognosis. Thymoma and a high concentration of receptor antibodies might both be caused by an unusually active immunological system. The marked decrease in receptor antibody concentration during treatment with immunosuppressive drugs could be explained by the relatively greater inhibitory effect on receptor antibody synthesis in these patients.
During lymph drainage the catabolism of IgG is increased but the synthesis is probably not affected (Strober et al., 1967) . By using a mathematical model to analyse the kinetic behaviour of the different IgG fractions we could show that the half life of the receptor antibody in the -three patients studied was two to three days, as com-pared with five to seven days for IgG subclass 3, and 15 to 25 days for total IgG (Lefvert, submitted for publication). Two other patients had half lives for the receptor antibody of 0.9 and seven days, respectively. The patient with antibody half life of 0.9 days was the only one who did not improve during the drainage. The concentration of receptor antibody decreased only 10%. Obviously, in this patient the synthesis of receptor antibody was so rapid that the increased catabolism during lymph drainage was almost fully compensated. The patient with an antibody half life of seven days had a complete remission, and was free from symptoms for more than one week after the period of drainage.
The great advantage of procedures such as lymph drainage and plasmapheresis is the rapid effect. But, considering the metabolic behaviour of the receptor antibody, it should be more effective to inhibit the synthesis than to try to deplete the antibody by protein drainage. In our patients, the removal of normal IgG was more efficient than the removal of receptor antibody during drainage. Treatment with corticosteroids and azathioprine, on the other hand, had a much greater effect on receptor antibody concentration than on the concentration of normal IgG.
As we have reported earlier (Lefvert and Pirskanen, 1977) The report on neonatal myasthenia gravis by Keesey et al. (1977) describes the persistence of IgG receptor antibodies in a baby as long as four months after birth. This is in contrast to the rapid disappearance of receptor antibodies in our cases.
In this study the two babies with receptor antibodies were free from myasthenic symptoms. This suggests that additional factors exist besides a passive transfer of maternal receptor antibodies. One explanation could be antigenic difference between the mother and the child. Another 
